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Abstract
Background: pressurized intraperitoneal aerosol chemotherapy (PIPAC), with or without electrostatic precipitation
(ePIPAC), was recently introduced in the treatment of peritoneal metastases (PM) from ovarian cancer (OC).
Preliminary clinical data are promising, but several methodological issues as well the anticancer efficacy of PIPAC
remain unaddressed. Here, we propose a rat ePIPAC model that allows to study these issues in a clinically relevant,
reproducible, and high throughput model.
Methods: laparoscopy and PIPAC were established in healthy Wistar rats. Aerosol properties were measured using
laser diffraction spectrometry based granulometric analyses. Electrostatic precipitation was accomplished using a
commercially available generator (Ultravision™). A xenograft model of ovarian PM was created in athymic rats using
intraperitoneal (IP) injection of SKOV-3 luciferase positive cells. Tumor growth was monitored weekly by in vivo
bioluminescence imaging.
Results: PIPAC and electrostatic precipitation were well tolerated using a capnoperitoneum of 8 mmHg. All rats
survived the (e)PIPAC procedure and no gas or aerosol leakage was observed over the entire procedure. With an
injection pressure of 20 bar, granulometry showed a mean droplet diameter (D(v,0.5)) of 47 μm with a flow rate of
0.5 mL/s, and a significantly lower diameter (30 μm) when a flow rate of 0.8 mL/s was used. Experiments using IP
injection of SKOV-3 luciferase positive cells showed that after IP injection of 20 × 106 cells, miliary PM was observed
in all animals. PIPAC was feasible and well supported in these tumor bearing animals.
Conclusions: we propose a reproducible and efficient rodent model to study PIPAC and ePIPAC in OC xenografts
with widespread PM. This model allows to characterize and optimize pharmacokinetic and biophysical parameters,
and to evaluate the anti-cancer efficacy of (e)PIPAC treatment.
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Background
Selected patients with peritoneal metastases (PM)
benefit from cytoreductive surgery (CRS) combined with
hyperthermic intraperitoneal chemoperfusion (HIPEC)
[1, 2]. However, many patients present with irresectable
disease, which has a dismal prognosis. Survival in
patients with irresectable PM from colon cancer is 15
months, from gastric cancer 4 months, and from pancre-
atic cancer only 6 weeks [3–5]. Systemic chemotherapy
is relatively inefficient in PM due to poor vascularity of
peritoneal tumor nodules [6, 7]. Pressurized intraperito-
neal aerosol chemotherapy (PIPAC) is a novel locoregio-
nal treatment modality which involves intraperitoneal
(IP) delivery of chemotherapy as an aerosol during
laparoscopic surgery [7, 8]. Chemotherapy is aerosolized
in the abdominal cavity using a high-pressure injector
and a nebulizer (Capnopen®). This method allows
aerosolized chemotherapy to interact directly with tumor
tissue. In addition, the elevated intra-abdominal pressure
may enhance tumor tissue drug penetration [9].
Despite the significant potential of PIPAC and the
preliminary clinical data already available, many techno-
logical and anti-cancer properties of the technique re-
main to be elucidated. In recent clinical practice, PIPAC
was combined with electrostatic aerosol precipitation
using the Ultravision™ system [10]. This device, originally
developed to clear smoke from the laparoscopic operat-
ing field by an electrostatic force, uses a stainless-steel
microfilament brush (Ionwand™) which is inserted into
the abdominal cavity [11]. A high DC voltage (7.5–9.5
kV, ≤ 10 μA) is applied to the Ionwand, resulting in a
corona discharge and a stream of negatively charged
ions, which attach to suspended particles. These now
negatively charged aerosol particles are attracted to the
positive charge of the return electrode. In theory, the
combination of electrostatic precipitation with PIPAC,
termed ePIPAC, can result in increased tissue uptake of
the aerosolized chemotherapy. However, this theoretical
advantage remains to be confirmed in well-designed
preclinical as well as clinical studies [12].
Several in vitro experimental PIPAC models have been
described. The cytotoxic efficacy of PIPAC was investi-
gated in vitro using proliferation assays of human colon
cancer cells [13]. An in vitro model consisting of aerosol
generation in a plastic box that contains human periton-
eum with PM was used to study tissue penetration of
doxorubicin, as well as the effect of treatment parame-
ters such as nebulizer position, pressure, and drug dose
[14, 15]. Schnelle et al. developed an interesting ex vivo
model that consists of an inverted bovine urinary
bladder, resulting in a serosa-lined cavity that can be
used to study PIPAC [16]. Solass and coworkers demon-
strated the technical proof of principle of PIPAC in a pig
model [17]. However, the pig model is cumbersome,
labour intensive, and expensive, and does not allow to
study anticancer properties in xenografted or syngeneic
PM. Here, we report the first small animal model of
PIPAC and ePIPAC that allows to study several import-
ant endpoints such as tissue penetration and anti-cancer
efficacy in PM of human origin.
Methods
Granulometric analyses
Volume-weighted particle size distribution (PSD) of
aerosol droplets was performed in triplicate by laser
diffraction (Mastersizer S long bench, Malvern
Instruments, Worcestershire, United Kingdom). The size
of aerosol droplets was measured in an open laser beam
(water vs. air, refractive index of 1.33 and 1.00 respect-
ively) using a 300F lens (0.5–900 μm) over a time
horizon of 10 to 20 s after initiation of injection. Saline
was nebulized using a commercially available nebulizer
(Capnopen®, Capnomed, Zimmern, Germany) and a
high-pressure injector (Injektron™ 82M, Medtron,
Saarbrücken, Germany). The outlet of the nebulizer was
perpendicularly secured at a distance of 35 mm to the
beam and 100 mm to the lens. The laser diffraction mea-
surements were performed as soon as the high-pressure
injector achieved the desired injection conditions, i.e. 10
s after initiating the injection. Results are expressed by
median of volume distribution, D(v,0.5), i.e. the size at
which 50 vol% of the droplets were either finer or
coarser than the predicted value, with standard
deviation.
Ex vivo simulation of PIPAC
A 12mm balloon trocar (Kii, advanced fixation sleeve,
Applied Medical, Amersfoort, The Netherlands) was
inserted in a closed 100mL ethylene vinyl acetate (EVA)
bag. CO2 was insufflated to establish a constant pressure
of 8 mmHg. Twenty mL of undiluted royal blue ink
(Pelikan nv, Groot-Bijgaarden, Belgium) was nebulized
into the EVA bag with a flow rate of 0.8 mL/s and a
maximal upstream injection pressure of 20 bar. The
nebulizer was fixed either perpendicularly to the surface
of the EVA bag, or in a slightly tilted position.
Animals
Adult Wistar Hannover rats (n = 3 preliminary experi-
ment; n = 6 in vivo experiment; Envigo, Horst, The
Netherlands) and adult athymic nude rats (n = 9; Envigo,
Horst, The Netherlands) were allowed to acclimatize to
the surroundings for at least three days and were kept in
standard housing conditions with water and food ad
libitum and a 12 h light/dark cycle. After the experi-
ments, all rats were euthanized with a lethal injection of
T-61 (0.3 mL/kg, IV) into the tail vein. The experiments
were approved by the Animal Ethical Committee of the
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Faculty of Medicine of Ghent University, Belgium (ECD
17–50 and ECD 18–30).
Surgical methods
Experimental protocol of PIPAC in rats
The experimental procedure of PIPAC in the rat was
based on clinical treatment protocols [18, 19]. Adult
Wistar Hannover rats (n = 6) were anesthetized with
sevoflurane (8 vol% induction, 4 vol% maintenance).
Animals were placed in a class II laminar flow hood
(Airstream, Esco Global, Barnsley, United Kingdom) in a
supine position and fixed at all four extremities. The
abdomen was shaved and disinfected. Next, a 5 mm and
a 12mm balloon trocar were inserted and a constant
capnoperitoneum pressure of 8 mmHg was established
(Olympus UHI-3 insufflator, Olympus Surgical Tech-
nologies Europe, Hamburg, Germany). Each trocar was
secured by a tripod. The nebulizer was then connected
to the high-pressure injector through a high-pressure
line and inserted into the abdominal cavity using the 12
mm trocar. Afterwards, a 5 mm laparoscope was intro-
duced into the abdominal cavity using the 5 mm trocar.
The tightness of the abdomen was documented via
absence of CO2 flow. Next, the high-pressure injector
was activated. Injection parameters were set at a flow
rate of 0.8 mL/s and a maximal upstream injection
pressure of 20 bar. When used with the nebulizer, the
high-pressure injector needs up to 10 s to achieve the
desired conditions (flow rate and injection pressure).
Therefore, the high-pressure injector was set to inject
8 mL of air during these first 10 s, before nebulizing
20 mL of saline at the desired conditions. The capno-
peritoneum pressure of 8 mmHg was maintained for
30 min. Thereafter, the aerosol was evacuated through
a closed aerosol waste system containing a 99.999%
ULPA-carbon filter. Finally, trocars were removed, and the
laparoscopic procedure was terminated. The abdomen was
closed with a two-layered running suture (Vicryl Plus 4–0
Ethicon, Johnson & Johnson international, Sint-Stevens-
Woluwe, Belgium) and analgesia was administered (Keto-
profen, 5mg/kg, SC).
Electrostatic precipitation
In three adult Wistar Hannover rats, the use of Ultravi-
sion™ technology (Alesi Surgical, Cardiff, United King-
dom) was added to the PIPAC-setup. The system was
activated at the start of aerosol generation and the elec-
tric current was maintained for 30 min. The Ultravision™
system integrates the following components: a generator
unit (voltage 7500–9500 V, current ≤ 10 μA), an active
cable terminating in an atraumatic stainless-steel brush
electrode (Ionwand) that is responsible for the electro-
static charging of aerosol particles, and a return elec-
trode with a solid return plate. To obtain a closed
electrical circuit, the solid return plate was fixed under a
metal plate. During the ePIPAC procedure, the rat was
positioned on this metal plate (Fig. 1).
Rat ovarian PM model
SKOV-3 Luc IP2 cells, a human ovarian carcinoma cell
line created by double in vivo selection of SKOV-3 Luc
cells, were used to create a rat xenograft model [20].
The cells (kindly donated by Olivier De Wever, Labora-
tory of Experimental Cancer Research, Ghent University)
were cultured at 37 °C in a 10% CO2 containing atmos-
phere in McCoy’s 5A medium (ThermoFisher Scientific
Bvba, Merelbeke, Belgium) supplemented with 10% fetal
bovine serum, penicillin and streptomycin (Thermo-
Fisher Scientific Bvba, Merelbeke, Belgium).
Athymic nude rats (n = 9) were injected IP with 5 ×
106 (n = 3), 10 × 106 (n = 3) or 20 × 106 (n = 3) SKOV-3
Luc IP2 cells in a volume of 5 mL saline. The rats under-
went a daily subcutaneous injection of cyclosporine (3
mg) starting three days prior to, and until four weeks
Fig. 1 A ePIPAC setup in a healthy Wistar Hannover rat. 12 mm balloon trocar with nebulizer and closed aerosol waste system (a), 5 mm balloon
trocar with laparoscope and CO2 insufflator (b), Ionwand (c), electrical conductor between return electrode (underneath metal plate) and
generator unit (d). B Intra-abdominal view of the Ionwand in a healthy Wistar Hannover rat
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after tumor cell inoculation to ensure tumor growth.
Tumor growth was monitored by weekly in vivo
bioluminescent imaging (BLI) (IVIS Lumina II, PerkinEl-
mer, Zaventem, Belgium). Imaging was performed 12
min after IP injection of D-luciferin (120 mg/kg; Perki-
nElmer, Zaventem, Belgium). The exposure time was
one second and the binning (resolution setting) was set
to medium.
After four weeks, PIPAC and ePIPAC with saline were
performed according to the abovementioned experimen-
tal procedures. The rats were euthanized 24 h after
(e)PIPAC with a lethal injection of T-61 (0.3 mL/kg, IV)
into the tail vein. Peritoneal tumors were excised and
embedded in paraffin for standard hematoxylin and
eosin (H&E) staining.
Statistical analysis
Differences between D(v,0.5) values were compared
using the non-parametric Mann-Whitney U test since
data were not normally distributed. A p-value of ≤ 0.05
was considered to indicate statistical significance.
Results
Influence of physical parameters on aerosol formation
A maximal upstream injection pressure of 20 bar and a
fixed flow rate of 0.5 mL/s were associated with a
D(v,0.5) of 47 ± 2 μm (Fig. 2a). Decreasing the maximal
upstream injection pressure to 10 bar, resulted in an
increased D(v,0.5) of 51 ± 1 μm (p = 0.127). However,
when the maximal upstream injection pressure was further
decreased to 5 bar, D(v,0.5) remained 51 ± 2 μm (p = 0.127).
Analysis of different flow rates (0.5 and 0.8 mL/s) at a
fixed maximal upstream injection pressure of 20 bar,
showed a strong impact on the volume-weighted PSD
curves (Fig. 2b). Applying a flow rate of 0.5 mL/s, D(v,0.5)
was 47 ± 2 μm. Increasing the flow rate to 0.8mL/s re-
sulted in a decreased D(v,0.5) of 30 ± 3 μm (p = 0.05).
Bimodal volume-weighted PSD curves were observed
when nebulization of saline was done in a closed environ-
ment using a plastic box (Fig. 2c). Aerosol formation in
patient-like conditions, i.e. nebulization of 200mL saline
with a maximal upstream injection pressure of 20 bar and
a flow rate of 0.5 mL/s in a plastic box of 5 L, showed a
D(v,0.5) of 35 ± 1 μm. After nebulization with rat-like con-
ditions, i.e. nebulization of 20mL with a maximal
upstream injection pressure of 20 bar and a flow rate of
0.8 mL/s in a plastic box of 100mL, a D(v,0.5) of 25 ±
3 μm (p = 0.05) was detected.
Adequacy of stain distribution throughout the entire
EVA bag was clearly superior with a slightly tilted
nebulizer position (Fig. 3). Specifically, the top of the
EVA bag was stained when the nebulizer was secured in
a tilted position, while this was not the case when it was
placed perpendicularly.
Experimental PIPAC procedure
Once the ideal injection parameters for (e)PIPAC were
determined, PIPAC with saline was tested in healthy
Wistar Hannover rats (n = 3). The feasibility of repeated
PIPAC applications was successfully tested in these
preliminary experiments. The three rats underwent three
consecutive PIPAC procedures with an interval of four
weeks. The rats tolerated multiple PIPAC applications
very well and were in good health after the third PIPAC
application. Thereafter, PIPAC (n = 3) and ePIPAC (n =
3) was performed in healthy adult Wistar Hannover rats.
Procedures were executed as planned in both groups.
The nebulizer enabled rapid and effective nebulization
of saline in the abdominal cavity without extracorporeal
leakage of aerosolized droplets over the entire setup. All
rats survived the procedures.
Rat ovarian PM model
In vivo BLI of tumor-bearing rats is illustrated in Fig. 4.
In the first (5 × 106 SKOV-3 Luc IP2 cells) and second
group (10 × 106 SKOV-3 Luc IP2 cells), no diffuse PM
was observed. After four weeks, two rats had only one
tumor nodule and in the other specimens no tumor
growth occurred. However, in the third group (20 × 106
SKOV-3 Luc IP2 cells) miliary PM was observed with a
tumor induction rate of 100% (3/3).
To assess whether it was possible to perform (e)PIPAC
in tumor bearing rats, this procedure was performed
with saline on day 28 in the athymic nude rats of group
3. All athymic nude rats survived this procedure. On day
29, the rats of group 3 were sacrificed and autopsy was
done. Diffuse PM with widespread small tumor nodules
could be demonstrated (Fig. 5). Tumor nodules were
embedded in paraffin before standard H&E staining was
conducted. H&E staining confirmed the presence of
tumor cells in the nodules (Fig. 6).
Discussion
The prognosis of patients with irresectable PM is poor,
with a median survival ranging from several weeks to
months [3–5]. Recently, PIPAC has been introduced in
clinical practice [21]. During PIPAC, chemotherapy is
delivered as an aerosol, generated by a nebulizer (Cap-
nopen®) connected to a high-pressure injector. This
novel approach may overcome two major limitations of
conventional liquid based IP chemotherapy: incomplete
coverage the peritoneal surfaces and poor tissue drug
penetration [22, 23]. The increased intra-abdominal
pressure during PIPAC by means of the capnoperito-
neum may overcome the high interstitial fluid pressure
in tumor tissue, and therefore improve tissue penetra-
tion [9]. Also, IP delivery of therapeutic agents as an
aerosol result in a more homogeneous distribution
compared to liquid instillation [12, 17, 21]. However, the
Van de Sande et al. BMC Cancer          (2019) 19:424 Page 4 of 10
Fig. 2 (See legend on next page.)
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biophysical, pharmacokinetic, and anticancer properties
and parameters that are relevant in PIPAC remain rela-
tively unknown. To date, four models were reported for
(e)PIPAC research: in vitro using cancer cells, an ex vivo
box model, an ex vivo bovine urinary bladder model and
an in vivo pig model [13–17, 24, 25]. We report a stan-
dardized rat model that allows to study biophysical,
pharmacokinetic, and anticancer properties of PIPAC
and electrostatic precipitation combined with PIPAC.
The first step was to ascertain that the model generates
an aerosol that is comparable to the clinical situation. In
clinical practice, the recommended settings are: nebuliza-
tion of a volume of 150 to 200mL, maximal upstream
injection pressure of 20 bar, flow rate of 0.5 mL/s and a
capnoperitoneum pressure of 12mmHg [21]. The result-
ing aerosol droplet size is reported to be in the range of
30–40 μm [26]. In vitro granulometric analyses performed
by Göhler et al. showed that the Capnopen® generated
aerosol consists of a bimodal volume-weighted PSD with a
D(v,0.5) of 25 μm [27]. The authors argue, based on theor-
etical assumptions and calculations, that the ideal droplet
size to obtain a gas-like behaviour should be 1.2 μm (for
Stokes numbers of Stk = 1) [27]. The droplet size of the
aerosol is indeed important for its physical behaviour in
the peritoneal cavity (diffusion versus sedimentation or
inertial impaction), but may also affect tissue penetration
of the administered cytotoxic agent [27, 28]. In pulmonary
medicine, only very small (< 5 μm) particles reach the
alveoles and exert a meaningful therapeutic effect.
[29–31] It should be noted that smaller particles carry
less drug mass, and that the anatomical restrictions
that apply to the respiratory tree do not apply to the
peritoneal cavity. For instance, large (> 10 μm) inhaled
particles tend to be deposited in the larynx or upper
airways, which is undesirable, but in PIPAC treatment
size considerations seem to be less important. Never-
theless, the current and ideal PIPAC droplet size, and
the biophysical parameters that affect it, should be
further characterized. In our model, analysis of
volume-weighted PSD curves demonstrated that
D(v,0.5) is 47 μm when a flow rate of 0.5 mL/s and a
maximal upstream injection pressure of 20 bar are
used (Fig. 2a). Increasing the flow rate to 0.8 mL/s re-
sulted in a statistically significant decrease of D(v,0.5)
to 30 μm, an observation in accordance with experi-
ence from nozzles used in inlet fogging of gas turbine
engines [32]. Interestingly, after nebulization of saline
in a plastic box, a bimodal volume-weighted PSD
distribution curves was observed, possibly explained
by aggregation of the injected aerosol droplets.
Next, we studied homogeneity of aerosol distribution
using a dye. It was observed that distribution of
undiluted royal blue ink is improved when the nebulizer
was held in a slightly tilted position; this could be
(See figure on previous page.)
Fig. 2 PSD curves of nebulized saline showing the distribution density (left curves) and cumulative distribution (right curves). Mean droplet
diameters were measured (n = 3 for each confirmation) in a range of 0.5 to 900 μm. The error bars show one time the standard deviation. a
Volume-weighted PSD curves showing the influence of maximal upstream injection pressure on D(v,0.5). 20 mL of saline was nebulized in open
space at a fixed flow rate of 0.5 mL/s and a maximal upstream injection pressure of 20 bar (blue graph), 10 bar (red graph) or 5 bar (black graph).
b Volume-weighted PSD curves illustrating the influence of flow rate on D(v,0.5). 20 mL of saline was nebulized in open space at a fixed maximal
upstream injection pressure of 20 bar and a flow rate of 0.5 mL/s (blue graph) or 0.8 mL/s (red graph). c Volume-weighted PSD curves
demonstrating the influence of the volume of the peritoneal cavity on D(v,0.5). To simulate a nebulization in a rat’s abdominal cavity, 20 mL of
saline was nebulized in a plastic box (V = 100mL) with a flow rate of 0.8 mL/s and a maximal upstream injection pressure of 20 bar (red graph).
200 mL of saline was nebulized in a plastic box (V = 5 L) with a flow rate of 0.5 mL/s and a maximal upstream injection pressure of 20 bar (blue
graph) as a comparison with the nebulization in human. The plastic boxes were bilaterally pierced to transvers laser light and a third perforation
was made at the top of the boxes to insert the nebulizer
Fig. 3 Distribution pattern of 20 mL undiluted royal blue ink. The injection parameters were set on a flow rate of 0.8 mL/s, a maximal upstream
injection pressure of 20 bar and an intracavitary pressure of 8 mmHg. a Blue ink distribution was limited to the bottom of the EVA bag when the
nebulizer was perpendicularly secured. b Complete staining of the EVA bag was observed when the nebulizer was placed in a tilted position
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explained by a longer travelling distance of the injected
aerosol droplets compared to the perpendicular position.
For the in vivo experiments, the pneumoperitoneum
pressure was set at 8 mm of Hg, since it is well known
that an intra-abdominal pressure of 12 mmHg is poorly
tolerated in rats [33, 34]. Preliminary results showed ex-
cellent tolerance of both PIPAC and electrostatic pre-
cipitation. With experience, the total procedure time
(from start to end of anesthesia) was ±100 min. The
ovarian cancer xenograft model, resulting in widespread
military PM, was successfully established after increasing
the number of SKOV-3 Luc IP2 cells to 20 × 106 and with
concurrent administration of cyclosporin. The required
number of cells may appear high, but it is known that athy-
mic rats have a lower degree of immune deficiency com-
pared to athymic mice [35]. This model now offers the
opportunity to study the anticancer effects of (e)PIPAC ei-
ther alone or in combination with systemic treatment. Since
immunotherapy offers considerable promise in ovarian can-
cer, the availability of a syngeneic OC model in immune
competent animals would allow to study PIPAC in combin-
ation with immunotherapy. A syngeneic rat OC model,
based on IP injection of NuTu-19 cells in female Fischer
344 rats, has been described [36], and may represent an in-
teresting future addition to the xenograft model that we
propose. Also, the use of immune competent animals al-
lows to study how PIPAC treatment affects the peritoneal
immune environment, a relevant parameter in the biology
of post-therapy recurrence.
The major limitation of our model is related to the
large difference in size between the rat and the human
peritoneal cavity. This requires scaling of the effects
found, and some clinical apparatus and methods may
work differently when used in a rat. As an example,
when using the clinically used electrostatic generator for
ePIPAC in a rat, the shorter distance between electrode
and grounding plate will result in a much stronger elec-
trical field (volt/meter). In the future, we will study ePI-
PAC using a custom made apparatus that allows to vary
voltage, current, and polarity.
Fig. 4 In vivo BLI of athymic nude rats inoculated with 5 × 106 (group 1), 10 × 106 (group 2) or 20 × 106 (group 3) SKOV-3 Luc IP2 cells (n = 3 in
each group). In the first and second group no diffuse PM was observed. One rat demonstrated tumor clearance, two rats had only one tumor
nodule and in the other specimens no tumor growth occurred. In the third group diffuse PM was observed with a tumor induction rate of 100%
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Fig. 5 Tumor nodules (white arrows) in athymic nude rats inoculated intraperitoneally with 20 × 106 SKOV-3 Luc IP2 cells. a Laparoscopic image
of the right upper abdomen. b Post-mortem view of the upper abdomen. c Intestines and mesentery
Fig. 6 H&E stainings of peritoneal implants at the parietal peritoneum (a) and mesentery (b), 40x magnification. In the right upper corner, a close
up of the H&E staining is shown, 400x magnification. The typical morphology of cancer cells can be detected
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Conclusion
We report the first reproducible small animal model of
PIPAC and ePIPAC in human ovarian PM bearing rats.
This model will allow to study essential technology re-
lated aspects, pharmacokinetics and tissue penetration,
and the activity of aerosolized anticancer therapies.
Abbreviations
BLI: Bioluminiscent imaging; CRS: Cytoreductive surgery; D(v,0.5): Median of
volume distribution; ePIPAC: Electrostatic aerosol precipitation with PIPAC;
EVA: Ethylene vinyl acetate; H&E: Hematoxylin and eosin;
HIPEC: Hyperthermic intraperitoneal chemoperfusion; IP: Intraperitoneal;
OC: Ovarian cancer; PIPAC: Pressurized intraperitoneal aerosol chemotherapy;
PM: Peritoneal metastases; PSD: Particle size distribution; Stk: Stokes number
Acknowledgements
The authors thank their lab technician Evelien Dierick for conducting H&E
stainings. We also thank the staff of Infinity IBiTech-MEDISIP (Christian Van
Hove and Benedicte Descamp) and Laboratory of Pharmaceutical Technol-
ogy (Valérie Vanhoorne and Chris Vervaet) for providing their devices. MS is
an ERS from the International Training Network ‘Nanomed’. Wim Ceelen is a
senior clinical investigator from the Fund for Scientific Research – Flanders
(FWO).
Funding
No funding was received.
Availability of data and materials
The datasets used and/or analyses during the study available from the
corresponding author on reasonable request.
Authors’ contributions
LVDS designed the ex vivo and in vivo experiments, KDC designed the
granulometric experiments. LVDS and KDC conducted the granulometric
experiments. LVDS performed the ex vivo simulation of PIPAC. LVDS and
WW made the (e)PIPAC rat model. LVDS and MS performed cell culturing.
LVDS made the rat ovarian PM model. LVDS performed data analysis. LVDS,
WW, SC, KR and WC discussed the results. LVDS has drafted the manuscript
and WW, SC, KR, WC substantively revised it. All authors read and approved
the final manuscript.
Ethics approval
The study protocol was approved by the Animal Ethical Committee of the
Faculty of Medicine, Ghent University, Belgium (ECD 17–50 and ECD 18–30).
The human cell lines did not require ethics approval from our institution as




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Laboratory of Experimental Surgery, Department of Human Structure and
Repair, Ghent University, Ghent, Belgium. 2Cancer Research Institute Ghent
(CRIG), Ghent University, Ghent, Belgium. 3Laboratory of Pharmaceutical
Technology, Department of Pharmaceutics, Ghent University, Ghent, Belgium.
4Laboratory for General Biochemistry and Physical Pharmacy, Department of
Pharmaceutics, Ghent University, Ghent, Belgium. 5Department of GI Surgery,
Ghent University Hospital, route 1275, C. Heymanslaan 10, B-9000 Ghent,
Belgium.
Received: 5 December 2018 Accepted: 30 April 2019
References
1. Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S,
Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2013;(2):CD008765.
https://doi.org/10.1002/14651858.CD008765.pub3.
2. Oseledchyk A, Zivanovic O. Intraoperative Hyperthermic intraperitoneal
chemotherapy in patients with advanced ovarian Cancer. Oncology
(Williston Park, NY). 2015;29:695–701.
3. Klaver YLB, Simkens LHJ, Lemmens VEPP, Koopman M, Teerenstra S,
Bleichrodt RP, de Hingh IHJT, Punt CJA. Outcomes of colorectal cancer
patients with peritoneal carcinomatosis treated with chemotherapy with
and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.
https://doi.org/10.1016/j.ejso.2012.03.008.
4. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K,
Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of
gastric origin: a population-based study on incidence, survival and risk
factors. Int J Cancer. 2014;134:622–8. https://doi.org/10.1002/ijc.28373.
5. Thomassen I, Lemmens VEPP, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh
IHJT. Incidence, prognosis, and possible treatment strategies of peritoneal
carcinomatosis of pancreatic origin: a population-based study. Pancreas.
2013;42:72–5. https://doi.org/10.1097/MPA.0b013e31825abf8c.
6. Winner KK, Steinkamp MP, Lee RJ, Swat M, Muller CY, Moses ME, Jiang Y,
Wilson BS. Spatial modeling of drug delivery routes for treatment of
disseminated ovarian cancer. Cancer Res. 2016;76:1320–34. https://doi.org/
10.1158/0008-5472.CAN-15-1620.
7. Tempfer CB. Pressurized intraperitoneal aerosol chemotherapy as an
innovative approach to treat peritoneal carcinomatosis. Med Hypotheses.
2015;85:480–4. https://doi.org/10.1016/j.mehy.2015.07.001.
8. Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner
M. Systematic review of pressurized intraperitoneal aerosol chemotherapy
for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017;
104:669–78. https://doi.org/10.1002/bjs.10521.
9. Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo J-
L, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B. High intra-abdominal
pressure enhances the penetration and antitumor effect of intraperitoneal
cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244:
106–12. https://doi.org/10.1097/01.sla.0000218089.61635.5f.
10. Reymond M, Demtroeder C, Solass W, Winnekendonk G, Tempfer C.
Electrostatic precipitation pressurized IntraPeritoneal aerosol chemotherapy
(ePIPAC): first in-human application. Pleura and Peritoneum. 2016;1:109–16.
https://doi.org/10.1515/pp-2016-0005.
11. Ansell J, Warren N, Wall P, Cocks K, Goddard S, Whiston R, Stechman M,
Scott-Coombes D, Torkington J. Electrostatic precipitation is a novel way of
maintaining visual field clarity during laparoscopic surgery: a prospective
double-blind randomized controlled pilot study. Surg Endosc. 2014;28:2057–
65. https://doi.org/10.1007/s00464-014-3427-8.
12. Kakchekeeva T, Demtröder C, Herath NI, Griffiths D, Torkington J, Solaß W,
Dutreix M, Reymond MA. In vivo feasibility of electrostatic precipitation as
an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC).
Ann Surg Oncol. 2016;23:592–8. https://doi.org/10.1245/s10434-016-5108-4.
13. Khosrawipour V, Diaz-Carballo D, Ali-Haydar A, Khosrawipour T, Falkenstein
TA, Wu D, Zieren J, Giger-Pabst U. Cytotoxic effect of different treatment
parameters in pressurized intraperitoneal aerosol chemotherapy (PIPAC) on
the in vitro proliferation of human colonic cancer cells. World J Surg Oncol.
2017;15:43. https://doi.org/10.1186/s12957-017-1109-4.
14. Solass W, Herbette A, Schwarz T, Hetzel A, Sun J-S, Dutreix M, Reymond MA.
Therapeutic approach of human peritoneal carcinomatosis with Dbait in
combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;
26:847–52. https://doi.org/10.1007/s00464-011-1964-y.
15. Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Foerster E,
Osma A, Adamietz IA, Zieren J, Fakhrian K. Evaluating the effect of micropump
(c) position, internal pressure and doxorubicin dosage on efficacy of
pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in an ex vivo model.
Anticancer Res. 2016;36:4595–600. https://doi.org/10.21873/anticanres.11008.
16. Schnelle D, Weinreich F-J, Kibat J, Reymond MA. A new ex vivo model for
optimizing distribution of therapeutic aerosols: the (inverted) bovine urinary
bladder. Pleura and Peritoneum. 2017;2:37–41.
https://doi.org/10.1515/pp-2017-0006.
Van de Sande et al. BMC Cancer          (2019) 19:424 Page 9 of 10
17. Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a
novel approach for intraperitoneal drug delivery and the related device.
Surg Endosc. 2012;26:1849–55. https://doi.org/10.1007/s00464-012-2148-0.
18. Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D,
Quenet F, Glehen O, Bakrin N, Passot G. Multicentric initial experience with
the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in
the management of unresectable peritoneal carcinomatosis. EJSO. 2017;43:
2178–83. https://doi.org/10.1016/j.ejso.2017.09.010.
19. Nowacki M, Alyami M, Villeneuve L, Mercier F, Hubner M, Willaert W, Ceelen
W, Reymond M, Pezet D, Arvieux C, Khomyakov V, Lay L, Gianni S, Zegarski
W, Bakrin N, Glehen O. Multicenter comprehensive methodological and
technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy
(PIPAC) interventions performed in 349 patients for peritoneal
carcinomatosis treatment: an international survey study. EJSO. 2018;44:991–
6. https://doi.org/10.1016/j.ejso.2018.02.014.
20. De Vlieghere E, Carlier C, Ceelen W, Bracke M, De Wever O. Data on in vivo
selection of SK-OV-3 Luc ovarian cancer cells and intraperitoneal tumor
formation with low inoculation numbers. Data Brief. 2016;6:542–9.
https://doi.org/10.1016/j.dib.2015.12.037.
21. Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren
J, Schwab M, Reymond MA. Intraperitoneal chemotherapy of peritoneal
Carcinomatosis using pressurized aerosol as an alternative to liquid solution:
first evidence for efficacy. Ann Surg Oncol. 2014;21:553–9.
https://doi.org/10.1245/s10434-013-3213-1.
22. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug
administration: tissue penetration and surface exposure. J Natl Cancer Inst.
1997;89:480–7. https://doi.org/10.1093/jnci/89.7.480.
23. Tempfer CB, Hilal Z, Dogan A, Petersen M, Rezniczek GA. Concentrations of
cisplatin and doxorubicin in ascites and peritoneal tumor nodules before
and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in
patients with peritoneal metastasis. Eur J Surg Oncol. 2018;44:1112–7.
https://doi.org/10.1016/j.ejso.2018.04.020.
24. Khosrawipour V, Khosrawipour T, Kern AJP, Osma A, Kabakci B, Diaz-Carballo
D, Förster E, Zieren J, Fakhrian K. Distribution pattern and penetration depth
of doxorubicin after pressurized intraperitoneal aerosol chemotherapy
(PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142:
2275–80. https://doi.org/10.1007/s00432-016-2234-0.
25. Tempfer C, Giger-Pabst U, Hilal Z, Dogan A, Rezniczek GA. Pressurized
intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis:
systematic review of clinical and experimental evidence with special
emphasis on ovarian cancer. Arch Gynecol Obstet. 2018;298:234–57.
https://doi.org/10.1007/s00404-018-4784-7.
26. Reymond MA, Solass W. PIPAC: pressurized IntraPeritoneal aerosol
chemotherapy – Cancer under pressure. Berlin: Walter de Gruyter GmbH &
Co KG; 2014.
27. Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA,
Zieren J, Stintz M, Giger-Pabst U. Technical description of the microinjection
pump (MIP®) and granulometric characterization of the aerosol applied for
pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc.
2016:1–7. https://doi.org/10.1007/s00464-016-5174-5.
28. Try C, Moulari B, Béduneau A, Fantini O, Pin D, Pellequer Y, Lamprecht A.
Size dependent skin penetration of nanoparticles in murine and porcine
dermatitis models. Eur J Pharm Biopharm. 2016;100:101–8.
https://doi.org/10.1016/j.ejpb.2016.01.002.
29. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® soft mist™
inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl).
2011;4:145–55. https://doi.org/10.2147/MDER.S7409.
30. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological
factors affecting therapeutic effectiveness of aerosolized medications. Br J
Clin Pharmacol. 2003;56:588–99.
https://doi.org/10.1046/j.1365-2125.2003.01892.x.
31. Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional
lung deposition – what evidence is there? Int J Pharm. 2011;406:1–10.
https://doi.org/10.1016/j.ijpharm.2010.12.040.
32. Chaker MA. Key Parameters for the Performance of Impaction-Pin Nozzles
Used in Inlet Fogging of Gas Turbine Engines 2005;4:91–97.
doi:https://doi.org/10.1115/GT2005-68346.
33. Niu X, Song X, Su A, Zhao S, Li Q. Low-pressure capnoperitoneum reduces
stress responses during pediatric laparoscopic high ligation of indirect
inguinal hernia sac. Medicine (Baltimore). 2017;96:e6563.
https://doi.org/10.1097/MD.0000000000006563.
34. Schmandra TC, Kim ZG, Gutt CN. Effect of insufflation gas and
intraabdominal pressure on portal venous flow during pneumoperitoneum
in the rat. Surg Endosc. 2001;15:405–8.
https://doi.org/10.1007/s004640000331.
35. Mashimo T, Takizawa A, Kobayashi J, Kunihiro Y, Yoshimi K, Ishida S, Tanabe
K, Yanagi A, Tachibana A, Hirose J, Yomoda J, Morimoto S, Kuramoto T,
Voigt B, Watanabe T, Hiai H, Tateno C, Komatsu K, Serikawa T. Generation
and characterization of severe combined immunodeficiency rats. Cell Rep.
2012;2:685–94. https://doi.org/10.1016/j.celrep.2012.08.009.
36. Azaïs H, Queniat G, Bonner C, Kerdraon O, Tardivel M, Jetpisbayeva G,
Frochot C, Betrouni N, Collinet P, Mordon S. Fischer 344 Rat: a preclinical
model for epithelial ovarian Cancer folate-targeted therapy. Int J Gynecol
Cancer. 2015;25:1194–200. https://doi.org/10.1097/IGC.0000000000000497.
Van de Sande et al. BMC Cancer          (2019) 19:424 Page 10 of 10
